Trial
NCT04214418
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Columbia University
Collaborators
Genentech, Inc.
Condition
Gastrointestinal Cancer
Intervention
Cobimetinib
Why stopped
Toxicity and Lack of Efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-18